Title X, the successful federal family planning program that prevented 20 million unintended pregnancies over five decades, faces dramatic policy changes under the Trump administration. New HHS guidelines redirect focus from effective contraception to fertility awareness methods with failure rates between 12-24%, compared to IUDs' less than 1% failure rate.

The funding shift prioritizes men's health concerns like erectile dysfunction while downplaying modern contraceptives. This aligns with anti-abortion and pronatalist interests, despite Title X having prevented an estimated 9 million abortions. The program hasn't fully recovered from previous cuts that halved patient numbers.

Business implications ripple through healthcare providers and pharmaceutical companies that supply contraception. The policy reversal ends a bipartisan consensus on family planning, potentially increasing healthcare costs as unintended pregnancies rise. For every dollar previously invested, the government saved $7 in Medicaid costs—a financial efficiency now at risk.